BeiGene
百济神州
Executive Summary
BeiGene is the only Chinese biotech to have built a global commercial infrastructure, with approved products (zanubrutinib/BRUKINSA) generating $2.5B+ in annual revenue across the US, Europe, and China. Unlike most Chinese biotechs that out-license to Western partners, BeiGene retains global rights and commercializes directly — making it both a competitor to and potential partner for Big Pharma. The company maintains dual listings (NASDAQ: BGNE, HKEX: 6160) and files 10-K annual reports with the SEC, providing unusually transparent corporate structure disclosure for a China-headquartered biotech. Co-founded by John Oyler (American) and Xiaodong Wang (Chinese Academy of Sciences), BeiGene's Western-Chinese dual leadership has been central to its credibility with US investors and regulators.
Structure: BeiGene operates through a traditional multinational structure with separate operating subsidiaries in the US, China, and Europe, avoiding complex VIE arrangements that complicate many Chinese biotechs. The company maintains dual headquarters in Beijing and San Mateo, with American founder-CEO John Oyler providing continuity and Western governance standards that simplify due diligence for US partners.
Key People
| Name | Title | Education | Flags |
|---|---|---|---|
John V. Oyler 欧雷强 | Founder, Chairman & CEO | BS, MIT; MBA, Stanford | |
Xiaobin Wu 吴晓滨 | President & COO | MD, China; MBA, Fordham University |
Ownership & Shareholder Structure
BeiGene → AstraZeneca
AstraZeneca invested $1B in BeiGene for 20% stake (2020). Strategic oncology collaboration including tislelizumab ex-China development.
BeiGene → Hengrui Medicine
BeiGene and Hengrui compete as top 2 Chinese innovative pharma by market cap and pipeline breadth.
Subsidiaries & Affiliates(3)
| Entity | Type | Jurisdiction | Scope | Flags | BIOSECURE |
|---|---|---|---|---|---|
BeiGene (Beijing) Co., Ltd. 百济神州(北京)生物科技有限公司 | operating | mainland china | Drug R&D, clinical development, and commercial operations in China. Manufactures Brukinsa and tislelizumab at Guangzhou facility. | NONE | |
BeiGene USA, Inc. | operating | us | US commercial and clinical operations. San Mateo HQ. Runs global clinical trials for Brukinsa and oncology pipeline. | NONE | |
BeiGene Switzerland GmbH | operating | us | European commercial operations and regulatory affairs. | NONE |
Corporate Events
BeiGene 10-K Annual Report
10-K annual report filed with SEC. Contains corporate structure, VIE disclosures, and risk factors.
Brukinsa becomes #1 BTK inhibitor globally
Brukinsa (zanubrutinib) surpassed AbbVie's Imbruvica in global quarterly sales for the first time. First China-originated drug to lead its global therapeutic class.
BIOSECURE Impact: None — BeiGene is a drug innovator, not a CDMO/CRO. No BIOSECURE exposure.
BeiGene rebrands global identity
BeiGene underwent global rebranding to emphasize its identity as a global oncology company rather than a Chinese biotech, reflecting maturation of its commercial infrastructure outside China.
Clinical Trials(50 total)
8
Phase 2
6
Phase 1
2
Other
4
Phase 1, Phase 2
| NCT ID | Interventions | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05690035 | Tislelizumab & Fruquintinib | Ph.2 | WITHDRAWN | 0 |
| NCT06803680 | BGB-B455, Chemotherapy | Ph.1 | RECRUITING | 90 |
| NCT06497062 | sonrotoclax, idarubicin/daunorubicin, Cytarabine, Azacitidine, allo-HSCT | Ph.2 | NOT YET RECRUITING | 47 |
| NCT06529523 | Tislelizumab | Ph.2 | RECRUITING | 40 |
| NCT06456138 | Trametinib, Anlotinib, Tislelizumab | Ph.1, Ph.2 | NOT YET RECRUITING | 60 |
| NCT06253195 | BGB-43395, Fulvestrant, Letrozole | Ph.1 | ACTIVE NOT RECRUITING | 33 |
| NCT05644626 | BGB-B167, Tislelizumab | Ph.1 | WITHDRAWN | 0 |
| NCT06091943 | Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet | Ph.1 | ACTIVE NOT RECRUITING | 62 |
| NCT06010303 | LBL-007, Tislelizumab, Chemotherapy Doublet | Ph.2 | ACTIVE NOT RECRUITING | 118 |
| NCT05890352 | Biospecimen Collection, Computed Tomography, Lenalidomide, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Tafasitamab, Tazemetostat, Zanubrutinib | Ph.2 | RECRUITING | 227 |
| NCT05844111 | [14C]-BGB-11417 | Ph.1 | COMPLETED | 6 |
| NCT05650723 | Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection | Ph.2 | ACTIVE NOT RECRUITING | 50 |
| NCT05640102 | Zanubrutinib | RECRUITING | 111 | |
| NCT05840835 | IMX-110 combined with Tislelizumab | Ph.1, Ph.2 | UNKNOWN | 60 |
| NCT05445648 | Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy | Ph.2 | UNKNOWN | 65 |
| NCT05590702 | First line therapy | ACTIVE NOT RECRUITING | 1,000 | |
| NCT06239532 | HAIC+TAE, Tislelizumab, Surufatinib | Ph.2 | ACTIVE NOT RECRUITING | 28 |
| NCT05471843 | BGB-11417 | Ph.1, Ph.2 | ACTIVE NOT RECRUITING | 125 |
| NCT05431270 | Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed | Ph.1, Ph.2 | RECRUITING | 40 |
| NCT05381909 | BGB-24714, Paclitaxel, Carboplatin, Docetaxel | Ph.1 | TERMINATED | 157 |
Showing 20 of 50 trials
Drug Molecules (ChEMBL)
TISLELIZUMAB
Phase 4ZANUBRUTINIB
Phase 4Top Publications (by citations)
Macrophages in immunoregulation and therapeutics.
Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y.
Targeting macrophages in cancer immunotherapy.
Duan Z, Luo Y.
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC.
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Yenerel MN, Illés A, Kay N, Garcia-Marco JA, Mato A, Pinilla-Ibarz J, Seymour JF, Lepretre S, Stilgenbauer S, Robak T, Rothbaum W, Izumi R, Hamdy A, Patel P, Higgins K, Sohoni S, Jurczak W.
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M.
Molecular targeted therapy for anticancer treatment.
Min HY, Lee HY.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA.
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.
Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JÁ, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P.
BIOSECURE Risk
Clear BIOSECURE status with no BCC designation, American founder-CEO leadership, and established US operations with San Mateo headquarters provide strong insulation from BIOSECURE restrictions
Mitigation: Company has proactively rebranded to emphasize global rather than Chinese identity and maintains substantial US commercial and clinical operations to reduce geopolitical risk
BD Intelligence
Therapeutic Areas:
Recent Deals: No specific recent out-licensing deals mentioned, suggesting BeiGene may be focused on in-house development and commercialization of their validated pipeline
Approach: Approach through US operations in San Mateo with focus on co-development or regional licensing opportunities. BeiGene's proven commercial success makes them an ideal partner for accessing validated oncology assets with global potential.
Red Flags
- ⚠Duplicate entries in key people and subsidiaries sections suggest data quality issues that should be verified during due diligence
Quick Facts
- Key People
- 2
- Subsidiaries
- 3
- CDMO/CRO Subs
- 0
- Genomics Subs
- 0
- Direct BIOSECURE
- 0
- Corp Events
- 3
- Gov-Connected
- 0
- Clinical Trials
- 50
- Publications
- 10
- Drug Molecules
- 2
- Relationships
- 3
Sources & Methodology
Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)
SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)
Publications: Europe PMC API (10 publications indexed)
Drug molecules: ChEMBL database (European Bioinformatics Institute)
Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)
Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures
Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)
Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.